In the present study we summarized the psychotropic beneficial effects and potential adverse effects of GLP-1RAs. Novel clinical and real-world studies may endorse the potential of GLP-1RAs in psychotropic disorders to improve mental health.
This systematic review aims to synthesize existing evidence on the effects of GLP-1 RAs on mental health outcomes, including both potential therapeutic benefits across various psychiatric disorders and the risk of associated adverse mental health effects.
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Analogues For Improving Mental Health.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for type 2 diabetes mellitus and obesity, are increasingly recognized for their significant impact on the central nervous system, leading to reports of both beneficial and adverse mental health effects.
Furthermore, GLP1-RA treatment was associated with improvements in both physical and mental healthrelated quality of life, as well as reduced emotional eating behaviors and increased eating restraint.
De Giorgi and colleagues present a comprehensive analysis of pre-clinical and clinical studies examining the role of glucagon-like peptide-1 receptor agonists in mental disorders.
:max_bytes(150000):strip_icc()/GLP-1sMightImpactYourMentalHealth_final-82971013116645c7809ea693b653c3fa.png "Not an 'Easy Way Out': How GLP-1 Users Navigate the Stigma of Weight ...")
